An interventional study of Atropine (0.01%) and Artificial tear in Myopia, sponsored by The Hong Kong Polytechnic University. Completed at 1 site in Hong Kong. Open to participants aged 7 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.
Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.
Among the 54 studies testing atropine in Myopia, this one is the 37th largest by enrollment, is one of 7 that started in 2018, is one of 13 with no phase, and was the 10th registered.
1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages 5–11
Ohio State University · Sites in United States
Ages 6–11 · Healthy volunteers
IDB VisionCare SDN BHD · Sites in Malaysia
Ages 5–10
Ocus Innovation Ireland Limited · Sites in Albania, Italy, Poland and 2 more countries
Ages 3–17
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
By country, each count listing its studies:
Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 7 Years to 10 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 16 · Phase 4 8
First in 2005; this study’s year is marked. 7 started in 2018.
This study's enrollment of 71 is below the median of 79 across 926 interventional studies indexed under Myopia.
Median enrollment 144 across the 54 interventional studies. Of the 23 that completed or were terminated, 6 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 54 have an industry lead sponsor. The 10 most frequent:
The Hong Kong Polytechnic University is the lead sponsor of 681 studies on the registry; 259 are open to participants now.
36 studies in Myopia by The Hong Kong Polytechnic University: 9 open now, 13 under way, none of them phase 3. Of 22 finished, 7 (32%) have results posted.
Among the 36 studies in Myopia by The Hong Kong Polytechnic University, this one is the 21st largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2018, is one of 32 with no phase, and was the 16th registered.
The Hong Kong Polytechnic University’s Myopia studies by the year they started, since 2007.
8 of the studies testing atropine in Myopia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT07329777Phase 3IDB VisionCare SDN BHDAtropine in the Treatment of Myopia Study in Malaysia | 2027-09 |
| NCT07164092Phase 3Mansoura UniversityEfficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center | 2027-09 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
| NCT05379855Eye & ENT Hospital of Fudan UniversityA-eyedrops on Ocular Alignment and Binocular Vision | 2027-02-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 54 studies testing atropine in Myopia, from their registry updates:
Among The Hong Kong Polytechnic University’s 36 in Myopia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Our project is a 24-month longitudinal randomized controlled trial that aims to investigate the myopia development after topical application of 0.01% atropine in children with either fast or slow myopia progression classified according to their initial electro-retinal responses. This will help elucidate the effectiveness of using low concentration atropine for myopia control in children with different myopia progression rates.
Inclusion Criteria:
Group receiving atropine treatment for 18 months
Drug: Atropine (0.01%)
Group receiving placebo for 18 months
Drug: Artificial tear
tropical application
tropical application
Annualized Changes in Refractive Error (SER)
Annualized changes in refractive error (SER) after receiving the 0.01 atropine or artificial tears up to 18 months
Time frame: 18 months
Annualized Change in Axial Length
Annualized change in axial length after receiving the 0.01 atropine or artificial tears up to 18 months
Time frame: 18 months
Recruitment period: Feb 2018 - Oct 2018 Location: HK PolyU Optometry clinic
| Milestone | Atropine 0.01% | Artifical Tear |
|---|---|---|
| Started | 36 | 35 |
| Completed | 34 | 27 |
| Not completed | 2 | 8 |
Annualized changes in refractive error (SER) after receiving the 0.01 atropine or artificial tears up to 18 months
| Dioptre/year | Atropine 0.01% | Artifical Tear |
|---|---|---|
| Annualized Changes in Refractive Error (SER) | -0.70 ± 0.39 | -0.66 ± 0.41 |
Annualized change in axial length after receiving the 0.01 atropine or artificial tears up to 18 months
| mm/year | Atropine 0.01% | Artifical Tear |
|---|---|---|
| Annualized Change in Axial Length | 0.3 ± 0.22 | 0.32 ± 0.16 |
Collected over 18 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atropine 0.01% | 0/34 (0%) | 0/34 (0%) | 0/34 (0%) |
| Artifical Tear | 0/27 (0%) | 0/27 (0%) | 0/27 (0%) |
| Age, Categorical(Participants) | Atropine 0.01% | Artifical Tear | Total |
|---|---|---|---|
| <=18 years | 34 | 27 | 61 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Atropine 0.01% | Artifical Tear | Total |
|---|---|---|---|
| Female | 17 | 13 | 30 |
| Male | 17 | 14 | 31 |
| Race and Ethnicity Not Collected(Participants) | Atropine 0.01% | Artifical Tear | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Atropine 0.01% | Artifical Tear | Total |
|---|---|---|---|
| Hong Kong | 34 | 27 | 61 |
| Refractive errors(Dioptre) | Atropine 0.01% | Artifical Tear | Total |
|---|---|---|---|
| Mean | -1.88 ± 1.08 | -1.74 ± 0.71 | -1.8 ± 0.95 |
| Electroretinogram(nV/deg^2) | Atropine 0.01% | Artifical Tear | Total |
|---|---|---|---|
| Mean | 41.65 ± 24.4 | 50.01 ± 27.75 | 45.16 ± 25.45 |
| Axial length(mm) | Atropine 0.01% | Artifical Tear | Total |
|---|---|---|---|
| Mean | 24.17 ± 0.79 | 24.09 ± 0.74 | 24.13 ± 0.76 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Dec 2019, 22 months.
Results were first posted in Oct 2024, 4 years 9 months after primary completion.
Of 200 non-industry interventional studies with no phase under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 22 months is below that.
Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atropine
The Hong Kong Polytechnic University →